Magnesium in the treatment of asthma.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review summarizing recent literature and meta-analyses without systematic review methodology.
PubMed 17218820 · doi:10.1097/ACI.0b013e328012ce4b
What was done
This narrative review synthesized recent research, updated meta-analyses of randomized controlled trials, and clinical practice audits regarding the use of oral, intravenous, and inhaled magnesium formulations in asthma management.
What was found
The abstract reports no numerical values or statistical effect sizes. Long-term oral magnesium supplementation does not lead to improved control in adult asthma. Updated meta-analyses confirm the efficacy of both intravenous and inhaled magnesium (as an adjuvant to nebulized salbutamol) for severe asthma exacerbations. Practice audits indicate widespread use of intravenous magnesium in North American emergency departments and emerging unregistered use of nebulized magnesium-salbutamol combinations.
Why it matters
It reinforces clinical guidance supporting intravenous and inhaled magnesium as adjunctive therapies in severe acute asthma exacerbations while highlighting that oral supplementation lacks efficacy for chronic control.
Limits
As a narrative review, it does not detail search methods, study quality scores, or sample sizes (n = ?). The abstract notes that findings are limited by a paucity of randomized controlled trials, with unresolved questions regarding optimal dosing regimens, administration routes, safety profiles, and subgroup-specific efficacy.
Cited by
- contradicts Having adequate magnesium has been shown to improve asthma.